search
Back to results

Zileuton and Exhaled Nitric Oxide in Asthmatics

Primary Purpose

Asthma

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
zileuton
Sponsored by
Gelb, Arthur F., M.D.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring asthma, nitric oxide gas exchange, lung function

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Non-smoking
  • Moderate to severe persistent asthmatics
  • Clinically stable X 6 weeks on Advair 250/50 bid for at least 12 months

Exclusion Criteria:

  • No leukotriene synthesis inhibitors or receptor antagonists for 6 weeks

Sites / Locations

  • Arthur F Gelb Medical Corporation

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

1

Arm Description

Advair 250/50 (baseline) fluticasone/salmeterol 250/50

Outcomes

Primary Outcome Measures

nitric oxide gas exchange including total exhaled nitric oxide, bronchial and alveolar nitric oxide

Secondary Outcome Measures

expiratory spirometry and asthma symptom Juniper score

Full Information

First Posted
December 15, 2007
Last Updated
December 18, 2007
Sponsor
Gelb, Arthur F., M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT00575861
Brief Title
Zileuton and Exhaled Nitric Oxide in Asthmatics
Official Title
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics
Study Type
Interventional

2. Study Status

Record Verification Date
December 2007
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Gelb, Arthur F., M.D.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
asthma, nitric oxide gas exchange, lung function

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Advair 250/50 (baseline) fluticasone/salmeterol 250/50
Intervention Type
Drug
Intervention Name(s)
zileuton
Other Intervention Name(s)
zyflo
Intervention Description
zileuton (Zyflo) 600mg qid for 2hr and for 30 days
Primary Outcome Measure Information:
Title
nitric oxide gas exchange including total exhaled nitric oxide, bronchial and alveolar nitric oxide
Time Frame
2 hr to 1 month
Secondary Outcome Measure Information:
Title
expiratory spirometry and asthma symptom Juniper score
Time Frame
2 hr to 1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Non-smoking Moderate to severe persistent asthmatics Clinically stable X 6 weeks on Advair 250/50 bid for at least 12 months Exclusion Criteria: No leukotriene synthesis inhibitors or receptor antagonists for 6 weeks
Facility Information:
Facility Name
Arthur F Gelb Medical Corporation
City
Lakewood
State/Province
California
ZIP/Postal Code
90712
Country
United States

12. IPD Sharing Statement

Citations:
Citation
Gelb AF, Flynn Taylor C, Shinar C, et al. Additive role of zileuton on total exhaled, bronchial, alveolar nitric oxide in non-atopic moderate to severe persistent asthmatics on fluticasone 250/salmeterol 50. Chest 2006;130:163S
Results Reference
background
PubMed Identifier
16778266
Citation
Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006 Jun;129(6):1492-9. doi: 10.1378/chest.129.6.1492.
Results Reference
background
PubMed Identifier
15229098
Citation
Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004 Oct 1;170(7):737-41. doi: 10.1164/rccm.200403-408OC. Epub 2004 Jun 30.
Results Reference
background
PubMed Identifier
19467341
Citation
Gelb AF, Taylor CF, Simmons M, Shinar C. Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. Pulm Pharmacol Ther. 2009 Dec;22(6):516-21. doi: 10.1016/j.pupt.2009.05.003. Epub 2009 May 23.
Results Reference
derived

Learn more about this trial

Zileuton and Exhaled Nitric Oxide in Asthmatics

We'll reach out to this number within 24 hrs